<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11BA9F46-16B8-4410-A960-2C402F3AC5B0"><gtr:id>11BA9F46-16B8-4410-A960-2C402F3AC5B0</gtr:id><gtr:name>Mauna Kea Technologies</gtr:name><gtr:address><gtr:line1>9, rue d'Enghien</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11BA9F46-16B8-4410-A960-2C402F3AC5B0"><gtr:id>11BA9F46-16B8-4410-A960-2C402F3AC5B0</gtr:id><gtr:name>Mauna Kea Technologies</gtr:name><gtr:address><gtr:line1>9, rue d'Enghien</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/670260BC-6C2F-4969-AC3A-605AC2879977"><gtr:id>670260BC-6C2F-4969-AC3A-605AC2879977</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Haslett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF45F1F2-0B54-4F94-80A0-BDEB55AB45BF"><gtr:id>FF45F1F2-0B54-4F94-80A0-BDEB55AB45BF</gtr:id><gtr:firstName>Tim</gtr:firstName><gtr:surname>Walsh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8A4C5E2A-12F6-4C90-866A-B6766FD57232"><gtr:id>8A4C5E2A-12F6-4C90-866A-B6766FD57232</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Brealey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/36B6C31F-AEF8-46B4-A57A-EE690EC04394"><gtr:id>36B6C31F-AEF8-46B4-A57A-EE690EC04394</gtr:id><gtr:firstName>Kev</gtr:firstName><gtr:surname>Dhaliwal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ010901%2F1"><gtr:id>65A50BF7-5CB0-4E68-BDAA-EF4DE6784FA8</gtr:id><gtr:title>Developmental Clinical Studies-validation of the utility of a novel smartprobe detecting neutrophil activation/elastase activity in acute lung injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J010901/1</gtr:grantReference><gtr:abstractText>40% of all patients in the intensive care unit (ICU) need a ventilator to support their lungs, with many associated complications. Currently the main indication of clinical deterioration is the presence/spreading of shadowing on the chest x- ray. This has many different causes (all requiring different treatments). There is a pressing need for rapid bedside tests to provide definitive diagnostic information about what is happening in the lungs themselves. Many studies have used blood markers, but in patients with multi-system disease these are not specific for the lung and the results are too slow to be useful in the rapidly-changing ICU setting.
We will employ cutting-edge technology to pass a tiny optical fibre deep into the lungs of ventilated patients and spray a 'microdose' of an imaging agent that will tell us the reasons for the lung deterioration. This approach has the potential to rapidly determine, at the bedside, if the lung shadowing is due to inflammation. Such an approach could revolutionise the way we deal with the critically ill patient and provide rapid, point of care diagnostics that would help tailor the patient's management.</gtr:abstractText><gtr:technicalSummary>a) Healthcare need addressed:
To allow clinicians in intensive care units (ICU) to rapidly and accurately determine the aetiology of deteriorating respiratory function or clinical status suggested, for example, by new infiltrates on the chest x-ray (CXR). 
b) The technology/solution:
We will employ a combined approach utilising recent advances in bronchoscopic confocal imaging for bedside-based, in situ real-time imaging together with the local, microdosed, instillation of next-generation 'smart' molecular probes targeting neutrophil activation (NAP). This will allow patient delineation for specific drug targeting and stratify/inform clinicians immediately for prognosis: specifically the presence and activity of neutrophils. 
c)Methodology:
The study will be conducted in two phases. The first involves administering NAP to healthy volunteers with experimental lung inflammation. The second phase moves to a 100-patient clinical study in ICU. NAP will be delivered directly into inflamed lungs and 'heat maps' of pulmonary neutrophil dependent lung injury will be generated by pCLE.
d) Impact on healthcare: 
Accurate, dynamic cellular/molecular diagnosis would lead to stratification of patient care and tailored prescribing patterns, including the use/non-use of expensive and potentially toxic anti-bacterials and ultimately reduced ventilator dependency and reduced mortality and morbidity in critically ill patients. This approach is applicable to disease detection/stratification/therapeutic intervention in other organs accessible by fibreoscopy.</gtr:technicalSummary><gtr:potentialImpactText>Impacts on Patients, Patient Pathways: Rapid and accurate bedside testing for pulmonary inflammation is a &amp;quot;holy grail&amp;quot; for modern critical care. Currently clinicians are faced with significant uncertainty in relation to triggers to commence treatment, the choice of agents, and especially the clinical confidence to de-escalate therapy. These issues are barriers to effective antibiotic stewardship, because of the proven association between delayed and inadequate antibiotic therapy and adverse clinical outcomes. Direct, bedside pulmonary molecular imaging provides the potential to break this cycle of uncertainty at an early stage, resulting in more appropriate antibiotic use, improved clinical outcomes, and reduced financial burden to healthcare organisations. 
 
Greater characterisation of pulmonary inflammation in real-time provides the potential to target existing and novel therapies and detect early predictors of clinical response. For example, despite negative clinical trials, steroids are widely used in ALI. Smartprobes offer the potential to improve the risk/benefit profile of steroid therapy and other existing and new therapies by enabling cell-specific effects to be measured in the individual patient. Similar approaches have been proposed for sepsis therapies based on point-of-care blood tests, but these have flaws (outlined above) and our proposed technology is a novel approach to directly characterise disease and its response to therapy deep in the human lung; the organ failing most frequently during critical illness. 

A quantitative estimate of the scale of potential benefits at a population level is difficult to assess but given that 40% of all ventilated patients have a diagnosis of ALI/ARDS and there are no current strategies for monitoring therapeutic efficacy of interventions or stratifying patients, this technology offers a unique opportunity to ICU, and the potential healthcare benefits are likely to be considerable. Given the unmet need in ICU, we foresee no major barriers to the translation of this technology in multi-centre trials and subsequent widespread clinical application. The equipment is truly 'bedside' and the proposed programme of research will generate sufficient quantities of each probe to study up to 10,000 patients. 

Pharma are actively interested in screening drugs in in vivo, hence a major impact will be on the provision of cutting-edge assays to assess drug response in situ in patients with lung disease.

Regarding wealth formation for the public, there is a direct opportunity to take the products of this research into a new small business enterprise and create jobs to develop similar molecular optical imaging probes using the same development pathway. This technological approach to apply cutting-edge chemistry with state of the art physics to detect optical molecular signatures deep within human tissue in critically ill patients is internationally unique and brings significant scientific impact and prestige to the multidisciplinary UK team and health service framework prosecuting the work.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1975335</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cleveland Clinic</gtr:description><gtr:id>F9E53B14-8E11-4743-98EB-A7B0AEE36BC4</gtr:id><gtr:impact>The Cleveland Clinic has successfully received an eIND from the FDA to perform clinical studies using imaging agents that have been developed by the team at Edinburgh.</gtr:impact><gtr:outcomeId>56dc1e68346a67.64903033-1</gtr:outcomeId><gtr:partnerContribution>Access to patients and clinical network input to initiate clinical trials.</gtr:partnerContribution><gtr:piContribution>Developing a collaborative partnership to expedite the implementation of optical molecular imaging in the USA and in particular in respiratory medicine. Exchanging ideas, projects and clinical protocols for the Cleveland Clinic to begin initiating an optical imaging programme in Respiratory Medicine using imaging agents developed in Edinburgh</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Guys</gtr:description><gtr:id>35E29AD0-F0DB-4973-BB6E-DC38B0EA9FAC</gtr:id><gtr:impact>Successful GMP manufacture of optical imaging agents for clinical trials</gtr:impact><gtr:outcomeId>56dc2408cc6371.56258403-1</gtr:outcomeId><gtr:partnerContribution>Providing academic rates for sterile fill GMP production so that we can complete clinical studies</gtr:partnerContribution><gtr:piContribution>Developing a sterile fill collaboration with the Guys NIHR facility</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mauna Kea Technologies</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Mauna Kea Technologies</gtr:description><gtr:id>F7D14763-432A-4EA3-895B-91806B44F00C</gtr:id><gtr:impact>Development and delivery of 40 clinical catheters to our group.</gtr:impact><gtr:outcomeId>56dc1ff8a31761.30614371-1</gtr:outcomeId><gtr:partnerContribution>Manufacture, quality management systems , sterility validation</gtr:partnerContribution><gtr:piContribution>Developing a delivery catheter to deliver optical imaging agents to the distal lung. We tested prototypes, contributed to the risk assessment and also are performing the initial clinical trials of the catheter</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>UMCG- Netherlands</gtr:description><gtr:id>CBDF5CD1-C8C2-4400-A684-573C99566B28</gtr:id><gtr:impact>No outputs yet, as collaboration just initiated</gtr:impact><gtr:outcomeId>56dc1f17e12f09.60795883-1</gtr:outcomeId><gtr:partnerContribution>Clinical network and also help in clinical protocol development.</gtr:partnerContribution><gtr:piContribution>Access to our imaging reagents developed in Edinburgh to the critical care team in Groningen.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>11600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IRC award (Bradley/Dhaliwal/Haslett)</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K03197x/1</gtr:fundingRef><gtr:id>B439BCA3-8BE0-4D28-9182-1E83DC7737BE</gtr:id><gtr:outcomeId>QvF2X5UoE9j</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>This device was developed with Mauna Kea Technologies as part of a MICA award from the DCS award. The catheter has gone through extensive testing and has now been delivered to Edinburgh for clinical testing. It is a unique triple lumen catheter that is less than 1.7 mm in diameter and can access the working channel of the bronchoscope.</gtr:description><gtr:id>DE8A540C-E75A-4B5C-B48D-1DD012FB1CD3</gtr:id><gtr:impact>New collaboration with the University of Utah - Professor Bob Hitchcock. Dept of Engineering. 
Novel applications have led to GSK being interested in using the device for pulmonary drug deposition studies and a GSK investigator led study is now being planned.</gtr:impact><gtr:outcomeId>56dc219a4579d4.13306615</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Triple Lumen Bronchoscopic Delivery Device</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Currently undergoing phase 2 evaluation in the ICU. Ethics and sponsor risk assessments approved for a repeat dose delivery to ventilated incapacitated patients in the ICU 

A repeat dose GLP toxicology assessment has been completed with no toxicology concerns. NAP was delivered to rats at 700X human dose for 7 consecutive days intratracheally with no toxicology findings

Stability of the drug product now shows it has a 2 year shelf life at room temperature. 

Successful GMP manufacture of the drug product by the Guys NIHR Sterile fill unit.

Principal source of development is the MRC award.</gtr:description><gtr:id>76360827-C2E7-4B1B-943F-0A199B6A78AF</gtr:id><gtr:impact>International patent protection in all territories being pursued
Spin out of Edinburgh Molecular Imaging</gtr:impact><gtr:outcomeId>56db59a9e1af83.49765504</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>NAP</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Edinburgh Molecular Imaging</gtr:companyName><gtr:description>SME that is focussing on Optical Molecular Imaging and the rapid commercialisation of in vivo optical imaging agents for human disease</gtr:description><gtr:id>5CAFA0AB-5299-4919-A512-995C31F98458</gtr:id><gtr:impact>Raised &amp;pound;4M Series A. Awarded Innovate UK award.</gtr:impact><gtr:outcomeId>56db533dd03a98.30306163</gtr:outcomeId><gtr:url>http://www.edinimage.com</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>84139EB9-97D6-4EBA-A7C3-D31BF9589BD5</gtr:id><gtr:title>A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc797cd3a172aa8fe324b25328d15fb5"><gtr:id>dc797cd3a172aa8fe324b25328d15fb5</gtr:id><gtr:otherNames>Barr LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16194_24_23627345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C96EC60-680A-4F24-91FC-F07DB29D2837</gtr:id><gtr:title>Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients.</gtr:title><gtr:parentPublicationTitle>British journal of anaesthesia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7f730c06e18455fc8fcea0cdb66c2d"><gtr:id>6d7f730c06e18455fc8fcea0cdb66c2d</gtr:id><gtr:otherNames>Conway Morris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0912</gtr:issn><gtr:outcomeId>pm_16194_24_23756248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3E0964-B8B6-4959-8B36-CEEEFDAE363A</gtr:id><gtr:title>Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aeb0c67fdf9cb4756bd82fe23617d8f"><gtr:id>5aeb0c67fdf9cb4756bd82fe23617d8f</gtr:id><gtr:otherNames>Lucas CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c00db016aff7.66333680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3C41FB8-06A1-44A8-811E-0AB7F0E0079A</gtr:id><gtr:title>The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58c00daf7b3f69.06982326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D9C6B7-7511-448F-94C8-387012E5B89B</gtr:id><gtr:title>Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37c74cabd9fe17a83cfb20d2bd4f3e5"><gtr:id>e37c74cabd9fe17a83cfb20d2bd4f3e5</gtr:id><gtr:otherNames>Hoodless LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c00dafaf0336.84297112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C734287B-60A5-4683-96EB-4430FF1045E4</gtr:id><gtr:title>Technical advance: autofluorescence-based sorting: rapid and nonperturbing isolation of ultrapure neutrophils to determine cytokine production.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_16194_24_23667167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D268451-C69E-4D86-A371-11B2338530F0</gtr:id><gtr:title>Highly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18f288c92165e764eefc2343660d3bdc"><gtr:id>18f288c92165e764eefc2343660d3bdc</gtr:id><gtr:otherNames>Avlonitis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_16194_24_23715090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DD93255-4BF8-4368-A48F-248DACB09C52</gtr:id><gtr:title>In-situ imaging of neutrophil activation in the human alveolar space with neutrophil activation probe and pulmonary optical endomicroscopy</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5418ba6c03b1d7d2cfbf4bc37f74d0b"><gtr:id>f5418ba6c03b1d7d2cfbf4bc37f74d0b</gtr:id><gtr:otherNames>Craven T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56db51dc51bb97.83819207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9E72547-AE4D-4B00-8273-BB03A2CC5599</gtr:id><gtr:title>Surface-enhanced Raman scattering in cancer detection and imaging.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6d51c11279fc76c6170807af338f5d8"><gtr:id>f6d51c11279fc76c6170807af338f5d8</gtr:id><gtr:otherNames>Vendrell M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>pm_16194_24_23416096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00FD542B-6B56-4F3A-982B-DB3DC730C605</gtr:id><gtr:title>The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58c00dafdd9bb7.56301710</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J010901/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>